PHD fingers in human diseases: disorders arising from misinterpreting epigenetic marks.

Lindsey A Baker, C David Allis, Gang G Wang
Author Information
  1. Lindsey A Baker: The Rockefeller University, Laboratory of Chromatin Biology & Epigenetics, New York, NY 10065, USA.

Abstract

Histone covalent modifications regulate many, if not all, DNA-templated processes, including gene expression and DNA damage response. The biological consequences of histone modifications are mediated partially by evolutionarily conserved "reader/effector" modules that bind to histone marks in a modification- and context-specific fashion and subsequently enact chromatin changes or recruit other proteins to do so. Recently, the Plant Homeodomain (PHD) finger has emerged as a class of specialized "reader" modules that, in some instances, recognize the methylation status of histone lysine residues, such as histone H3 lysine 4 (H3K4). While mutations in catalytic enzymes that mediate the addition or removal of histone modifications (i.e., "writers" and "erasers") are already known to be involved in various human diseases, mutations in the modification-specific "reader" proteins are only beginning to be recognized as contributing to human diseases. For instance, point mutations, deletions or chromosomal translocations that target PHD fingers encoded by many genes (such as recombination activating gene 2 (RAG2), Inhibitor of Growth (ING), nuclear receptor-binding SET domain-containing 1 (NSD1) and Alpha Thalassaemia and Mental Retardation Syndrome, X-linked (ATRX)) have been associated with a wide range of human pathologies including immunological disorders, cancers, and neurological diseases. In this review, we will discuss the structural features of PHD fingers as well as the diseases for which direct mutation or dysregulation of the PHD finger has been reported. We propose that misinterpretation of the epigenetic marks may serve as a general mechanism for human diseases of this category. Determining the regulatory roles of histone covalent modifications in the context of human disease will allow for a more thorough understanding of normal and pathological development, and may provide innovative therapeutic strategies wherein "chromatin readers" stand as potential drug targets.

References

  1. Cell. 2004 Jan 23;116(2):299-311 [PMID: 14744439]
  2. EMBO J. 2003 Jun 16;22(12):3153-63 [PMID: 12805229]
  3. J Biol Chem. 2005 Aug 5;280(31):28701-10 [PMID: 15964836]
  4. Cell. 2007 Feb 23;128(4):693-705 [PMID: 17320507]
  5. Clin Lab Med. 2004 Mar;24(1):305-17 [PMID: 15157567]
  6. Gene Expr Patterns. 2007 Oct;7(8):858-71 [PMID: 17698420]
  7. Plant J. 1993 Jul;4(1):137-50 [PMID: 8106082]
  8. Mol Cell. 2007 Jan 12;25(1):15-30 [PMID: 17218268]
  9. Am J Hum Genet. 2003 Jan;72(1):132-43 [PMID: 12464997]
  10. Nat Genet. 1997 Dec;17(4):393-8 [PMID: 9398839]
  11. Cell. 1995 Mar 24;80(6):837-45 [PMID: 7697714]
  12. J Biol Chem. 2008 Feb 8;283(6):3006-3010 [PMID: 18077460]
  13. Oncogene. 2001 Sep 10;20(40):5695-707 [PMID: 11607819]
  14. EMBO J. 1998 Jun 15;17(12):3398-412 [PMID: 9628876]
  15. Nat Immunol. 2003 Jul;4(7):624-30 [PMID: 12830137]
  16. Blood. 2002 Sep 15;100(6):2145-52 [PMID: 12200379]
  17. Mol Cell Biol. 2008 Jan;28(2):705-17 [PMID: 17967883]
  18. Cancer Res. 1996 May 1;56(9):2171-7 [PMID: 8616868]
  19. Nat Genet. 2002 Dec;32(4):661-5 [PMID: 12415272]
  20. Hum Mol Genet. 2008 Jun 15;17(12):1774-82 [PMID: 18319327]
  21. EMBO J. 1996 Dec 2;15(23):6701-15 [PMID: 8978696]
  22. Nature. 2007 Oct 18;449(7164):928-32 [PMID: 17898715]
  23. J Biol Chem. 2008 Jun 6;283(23):15956-64 [PMID: 18381289]
  24. Nature. 2007 Aug 9;448(7154):714-7 [PMID: 17687327]
  25. Trends Mol Med. 2007 Sep;13(9):363-72 [PMID: 17822958]
  26. Orphanet J Rare Dis. 2006 May 04;1:15 [PMID: 16722615]
  27. Mol Cell. 2006 Dec 8;24(5):785-796 [PMID: 17157260]
  28. Immunity. 2007 Oct;27(4):561-71 [PMID: 17936034]
  29. Mol Cell Biol. 2000 Aug;20(15):5653-64 [PMID: 10891502]
  30. Science. 1996 Oct 4;274(5284):97-9 [PMID: 8810255]
  31. Annu Rev Immunol. 1996;14:459-81 [PMID: 8717521]
  32. Trends Biochem Sci. 2007 Nov;32(11):509-19 [PMID: 17949986]
  33. Mol Cell. 2007 Nov 30;28(4):677-91 [PMID: 18042461]
  34. Cancer Res. 2002 Apr 15;62(8):2203-9 [PMID: 11956069]
  35. Cell Mol Life Sci. 2004 Oct;61(19-20):2597-613 [PMID: 15526165]
  36. Nature. 2006 Jul 6;442(7098):96-9 [PMID: 16728974]
  37. Annu Rev Biochem. 2007;76:75-100 [PMID: 17362198]
  38. Mol Biol Cell. 2002 Apr;13(4):1282-97 [PMID: 11950939]
  39. Trends Mol Med. 2007 Sep;13(9):373-80 [PMID: 17822959]
  40. Nat Rev Genet. 2006 Jun;7(6):415-26 [PMID: 16708070]
  41. Genes Chromosomes Cancer. 2006 May;45(5):437-46 [PMID: 16419055]
  42. Nat Genet. 1996 Dec;14(4):415-20 [PMID: 8944021]
  43. Nature. 2007 Dec 13;450(7172):1106-10 [PMID: 18033247]
  44. Cancer Res. 2001 Jun 1;61(11):4345-9 [PMID: 11389058]
  45. Trends Immunol. 2008 Mar;29(3):133-40 [PMID: 18255337]
  46. Cell. 2007 Nov 16;131(4):822 [PMID: 18022374]
  47. Nature. 2006 Jul 6;442(7098):100-3 [PMID: 16728977]
  48. Hum Mol Genet. 1994 Nov;3(11):1957-64 [PMID: 7874112]
  49. Cancer Res. 2006 Jan 1;66(1):107-12 [PMID: 16397222]
  50. Annu Rev Immunol. 2000;18:495-527 [PMID: 10837067]
  51. Cell. 2007 Feb 23;128(4):683-92 [PMID: 17320506]
  52. Eur J Endocrinol. 2001 Apr;144(4):347-51 [PMID: 11275943]
  53. Nat Immunol. 2005 Feb;6(2):198-203 [PMID: 15619624]
  54. Blood. 2001 Jan 1;97(1):81-8 [PMID: 11133745]
  55. Nat Cell Biol. 2007 Jul;9(7):804-12 [PMID: 17589499]
  56. EMBO Rep. 2008 Apr;9(4):370-6 [PMID: 18292755]
  57. J Clin Invest. 2005 Feb;115(2):258-67 [PMID: 15668733]
  58. Cell. 1992 Mar 6;68(5):855-67 [PMID: 1547487]
  59. Clin Genet. 2006 Oct;70(4):348-54 [PMID: 16965330]
  60. Nat Rev Mol Cell Biol. 2007 Dec;8(12):983-94 [PMID: 18037899]
  61. Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):18993-8 [PMID: 18025461]
  62. J Biol Chem. 2000 Jun 2;275(22):16802-9 [PMID: 10748110]
  63. J Exp Med. 2005 Jul 4;202(1):33-45 [PMID: 15983066]
  64. J Clin Endocrinol Metab. 2000 Jan;85(1):460-3 [PMID: 10634424]
  65. Hum Mol Genet. 2000 Mar 1;9(4):539-47 [PMID: 10699177]
  66. Nat Struct Mol Biol. 2008 Apr;15(4):381-8 [PMID: 18345014]
  67. Mol Cell Biol. 2004 Mar;24(5):1884-96 [PMID: 14966270]
  68. Nature. 2006 Jul 6;442(7098):91-5 [PMID: 16728978]
  69. Blood. 2002 May 15;99(10):3857-60 [PMID: 11986249]
  70. Cell. 2007 Mar 9;128(5):889-900 [PMID: 17320163]
  71. Int J Oncol. 2003 Apr;22(4):927-31 [PMID: 12632089]
  72. Nat Genet. 1997 Dec;17(4):399-403 [PMID: 9398840]
  73. Nature. 2007 Aug 9;448(7154):718-22 [PMID: 17687328]
  74. J Med Genet. 2006 Mar;43(3):193-200 [PMID: 16118346]
  75. Cell. 2007 Feb 23;128(4):669-81 [PMID: 17320505]
  76. Nat Struct Mol Biol. 2007 Nov;14(11):1025-1040 [PMID: 17984965]
  77. Nature. 2000 Jan 6;403(6765):41-5 [PMID: 10638745]
  78. Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2709-14 [PMID: 17296936]
  79. Nat Genet. 2002 Apr;30(4):365-6 [PMID: 11896389]
  80. Mol Cell. 2006 Jan 6;21(1):51-64 [PMID: 16387653]
  81. Am J Hum Genet. 2000 Feb;66(2):378-92 [PMID: 10677297]
  82. Leukemia. 2007 Apr;21(4):842-4 [PMID: 17287853]
  83. J Cell Biochem. 2005 Dec 15;96(6):1127-36 [PMID: 16167330]
  84. Hum Mol Genet. 1998 Apr;7(4):679-84 [PMID: 9499421]
  85. Trends Biochem Sci. 2006 Jan;31(1):35-40 [PMID: 16297627]
  86. J Biol Chem. 2005 Mar 25;280(12):11505-12 [PMID: 15649886]
  87. J Clin Endocrinol Metab. 2007 Feb;92(2):595-603 [PMID: 17118990]
  88. Hum Mol Genet. 2003 Feb 15;12(4):441-50 [PMID: 12566391]
  89. Mol Cell Biol. 1999 Jan;19(1):764-76 [PMID: 9858599]
  90. Immunol Rev. 2004 Aug;200:165-81 [PMID: 15242404]
  91. Blood. 2005 May 15;105(10):4060-9 [PMID: 15677557]
  92. Clin Exp Immunol. 2004 Mar;135(3):348-57 [PMID: 15008965]
  93. N Engl J Med. 1965 Aug 19;273:427-32 [PMID: 14328107]
  94. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11939-44 [PMID: 17609377]
  95. Cell. 2007 Mar 23;128(6):1077-88 [PMID: 17320160]
  96. Cell. 1999 Aug 6;98(3):285-94 [PMID: 10458604]
  97. J Biol Chem. 2007 Jan 26;282(4):2450-5 [PMID: 17142463]
  98. Science. 2002 Nov 15;298(5597):1395-401 [PMID: 12376594]
  99. Trends Immunol. 2007 Jul;28(7):321-7 [PMID: 17556019]
  100. Mol Cell Biol. 2002 Feb;22(3):835-48 [PMID: 11784859]
  101. Hum Mutat. 2006 Dec;27(12):1174-84 [PMID: 16960852]
  102. Am J Hum Genet. 2005 Aug;77(2):193-204 [PMID: 15942875]
  103. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11577-82 [PMID: 14500909]
  104. Ann N Y Acad Sci. 2007 Jun;1106:114-42 [PMID: 17442773]
  105. Int J Oncol. 2004 Jul;25(1):73-80 [PMID: 15201991]
  106. Leukemia. 2003 Nov;17(11):2244-7 [PMID: 12931227]
  107. Nature. 1995 Jul 27;376(6538):348-51 [PMID: 7630403]
  108. Int J Biochem Cell Biol. 2005 May;37(5):1054-65 [PMID: 15743678]
  109. FASEB J. 2007 Nov;21(13):3705-16 [PMID: 17585055]
  110. Mol Cell Biol. 2008 Apr;28(8):2718-31 [PMID: 18285464]
  111. Oncogene. 2006 Feb 9;25(6):857-66 [PMID: 16170338]
  112. Nature. 2006 Jul 6;442(7098):86-90 [PMID: 16728976]

Grants

  1. R37 GM053512-30/NIGMS NIH HHS
  2. GM 53512/NIGMS NIH HHS
  3. T32 CA009673/NCI NIH HHS
  4. CA09673/NCI NIH HHS
  5. R37 GM053512/NIGMS NIH HHS

MeSH Term

Autoimmunity
DNA-Binding Proteins
Epigenesis, Genetic
Humans
Models, Genetic
Models, Molecular
Mutation
Neoplasms
Nervous System Diseases
Polycomb-Group Proteins
Syndrome
Transcription Factors

Chemicals

DNA-Binding Proteins
PHF1 protein, human
Polycomb-Group Proteins
Transcription Factors

Word Cloud

Created with Highcharts 10.0.0histonehumanPHDdiseasesmodificationsmarksmutationsfingerscovalentmanyincludinggenemodulesproteinsfinger"reader"lysinedisorderswillepigeneticmayHistoneregulateDNA-templatedprocessesexpressionDNAdamageresponsebiologicalconsequencesmediatedpartiallyevolutionarilyconserved"reader/effector"bindmodification-context-specificfashionsubsequentlyenactchromatinchangesrecruitRecentlyPlantHomeodomainemergedclassspecializedinstancesrecognizemethylationstatusresiduesH34H3K4catalyticenzymesmediateadditionremovalie"writers""erasers"alreadyknowninvolvedvariousmodification-specificbeginningrecognizedcontributinginstancepointdeletionschromosomaltranslocationstargetencodedgenesrecombinationactivating2RAG2InhibitorGrowthINGnuclearreceptor-bindingSETdomain-containing1NSD1AlphaThalassaemiaMentalRetardationSyndromeX-linkedATRXassociatedwiderangepathologiesimmunologicalcancersneurologicalreviewdiscussstructuralfeatureswelldirectmutationdysregulationreportedproposemisinterpretationservegeneralmechanismcategoryDeterminingregulatoryrolescontextdiseaseallowthoroughunderstandingnormalpathologicaldevelopmentprovideinnovativetherapeuticstrategieswherein"chromatinreaders"standpotentialdrugtargetsdiseases:arisingmisinterpreting

Similar Articles

Cited By